4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
2 citations
,
June 2005 in “Clinical Oncology” A man's bald spot grew hair after starting cancer treatment with gefitinib.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
1 citations
,
January 2020 Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.
Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
2 citations
,
May 2025 in “Archives of Dermatological Research” JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
4 citations
,
January 2025 in “JAAD reviews.” Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
17 citations
,
February 2019 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
36 citations
,
March 2009 in “Molecular Carcinogenesis” Disrupting Bcl-xL in mice reduces skin cancer risk.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
25 citations
,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
January 2019 in “Dermatologic Surgery” 169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
September 2020 in “Acta Scientific Cancer Biology” Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.